Table 1.

Autoimmune anti-BC RNA reactivity

Subjects	Diagnosis	Anti-BC RNA reactivity			n
		++	+	−
Group I	SLE with seizures	10 (36%)	12	6	28
Group II	SLE with OBS	4 (18%)	13	5	22
Group III	SLE	4 (21%)	11	4	19
Group IV	Healthy subjects	0	0	17	17
Group V	Rheumatoid arthritis	0	0	8	8
Group VI	Ulcerative colitis	0	0	1	1
Group VII	Multiple sclerosis	0	0	12	12

Reactivity is categorized as follows: ++, strong reactivity; +, weak reactivity; −, no reactivity. Reactivity to BC RNAs is specific to SLE patients (Groups I–III). Samples from healthy subjects with no evidence of disease (healthy subjects, Group IV) and samples from patients with autoimmune diseases other than SLE (i.e. RA, UC, MS; Groups V–VII) were found to be nonreactive. n refers to the total number of subjects in each group. Anti-BC RNA reactivity was established by EMSA analysis using ³²P-labeled BC200 RNA.